OrthoPediatrics Corp. Reports First Quarter 2025 Financial Results

OrthoPediatrics Corp., a company dedicated to advancing pediatric orthopedics, has released its financial results for the first quarter of 2025. The company reported a significant increase in revenue and provided an optimistic outlook for the remainder of the year.

Financial Highlights

For the first quarter of 2025, OrthoPediatrics reported a total revenue of $52.4 million, marking a 17% increase from $44.7 million in the same period last year. The company's gross profit also saw a rise, reaching $38.3 million, up 19% from $32.2 million in the first quarter of 2024. Despite these gains, the company reported a net loss of $10.7 million, compared to a net loss of $7.8 million in the previous year. The net loss per share was $0.46, up from $0.34 per share in the first quarter of 2024.

Business and Operational Highlights

OrthoPediatrics achieved several milestones in the first quarter of 2025. The company helped nearly 39,000 children, a record number for a single quarter. Revenue from Trauma & Deformity grew by 14%, while Scoliosis revenue surged by 34%. The company also launched the VerteGlide™ System, its 80th system, aimed at treating Early Onset Scoliosis (EOS).

Strategic Initiatives and Corporate Developments

OrthoPediatrics has increased its full-year 2025 revenue guidance to a range of $236.0 million to $242.0 million, representing a growth of 15% to 18% compared to the prior year. The company also anticipates achieving positive free cash flow in the fourth quarter of 2025. Additionally, the company has made strides in reducing its free cash flow usage by 35% compared to the same period last year.

Management's Perspective

David Bailey, President & CEO of OrthoPediatrics, expressed satisfaction with the company's performance, highlighting strong revenue and profitability. He emphasized the company's progress in scaling operations, gaining market share, and launching innovative products. Bailey also noted the company's robust U.S. manufacturing and supply chain, which positions it well for continued growth.

Future Outlook

Looking ahead, OrthoPediatrics has reiterated its annual set deployment target of $15.0 million and expects adjusted EBITDA for the full year to be between $15.0 million and $17.0 million. The company remains optimistic about its growth prospects for the rest of 2025 and beyond.

SEC Filing: ORTHOPEDIATRICS CORP [ KIDS ] - 8-K - May. 07, 2025